Live Feeds
● LIVE Updated 1h ago · 19 sources tracked

Genentech pays Alector $100M for preclinical Parkinson’s prospect

Genentech, part of Roche, has agreed to pay Alector $100 million upfront for exclusive worldwide rights to develop and commercialize AL050, an experimental preclinical therapy for Parkinson's disease and other neurodegenerative conditions. The global license agreement could bring Alector up to $1.17 billion in additional conditional development, regulatory, and commercial milestone payments, along with tiered royalties on future sales. AL050 is designed to target GCase deficiency by combining an engineered version of the GCase enzyme with Alector Brain Carrier technology to help cross the blood-brain barrier.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (19)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Genentech agreed to pay Alector $100 million upfront for exclusive worldwide rights to AL050.
  • ✓ The total value of the deal could reach up to $1.27 billion or $1.17 billion in conditional milestone payments.
  • ✓ AL050 is an investigational preclinical enzyme-replacement therapy designed to address GCase deficiency linked to Parkinson's disease.
  • ✓ The therapy combines an engineered GCase enzyme with Alector Brain Carrier technology to cross the blood-brain barrier.
🛡️ Source Corroboration: 19 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

Genentech acquired exclusive global rights to Alector's preclinical Parkinson's therapy AL050 in a deal worth up to $1.27 billion total.

Live updates

  1. Genentech Pays Alector $100M for AL050 Parkinson's Therapy

    Genentech, part of Roche, has agreed to pay Alector $100 million upfront for exclusive worldwide rights to develop and commercialize AL050, an experimental preclinical therapy for Parkinson's disease and other neurodegenerative conditions. The global license agreement could bring Alector up to $1.17 billion in additional conditional development, regulatory, and commercial milestone payments, along with tiered royalties on future sales. AL050 is designed to target GCase deficiency by combining an engineered version of the GCase enzyme with Alector Brain Carrier technology to help cross the blood-brain barrier.

    Why it matters

    The transaction grants Genentech full responsibility for development and commercialization of the preclinical drug candidate. Alector retains ownership of its brain-delivery platform while advancing the enzyme-replacement therapy toward clinical trials. The therapeutic program aims to address GCase deficiency, a known contributor to Parkinson's risk, particularly in patients with GBA1 mutations.

    What is confirmed

    • Genentech agreed to pay Alector $100 million upfront for exclusive worldwide rights to AL050.
    • The total value of the deal could reach up to $1.27 billion or $1.17 billion in conditional milestone payments.
    • AL050 is an investigational preclinical enzyme-replacement therapy designed to address GCase deficiency linked to Parkinson's disease.
    • The therapy combines an engineered GCase enzyme with Alector Brain Carrier technology to cross the blood-brain barrier.
    • Genentech takes over responsibility for development through commercialization.

    What to watch next

    • Progression of AL050 from preclinical development into human clinical trials
    • Achievement of future development, regulatory, and commercial milestones triggering payments
    Sources used for this update (20)
    1. github.com — nocache/README at master · Feh/nocache · GitHub
    2. classic.yarnpkg.com — nocache - Yarn
    3. developer.mozilla.org — Cache-Control header - HTTP | MDN - MDN Web Docs
    4. directory.fsf.org — Nocache - Free Software Directory
    5. github.com — GitHub - helmetjs/nocache: Middleware to disable client-side...
    6. learn.microsoft.com — CacheControlHeaderValue.NoCache Property (System.Net.Http.Headers...
    7. Fierce Biotech — Genentech pays Alector $100M for preclinical Parkinson’s prospect
    8. Reuters — Alector soars as Roche licenses Parkinson's therapy for up to $1.27 billion
    9. Yahoo Finance — Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases
    10. Stock Titan — A Parkinson’s drug deal could mean up to $1.17 billion for Alector if future goals are met.
    11. wboc.com — Biotech Brainiacs and Breakthroughs
    12. Longevity.Technology — Genentech pays $100m upfront for Alector’s AL050
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community